Bevacizumab Biosimilars Market Poised to Double by 2032 Driven by Rising Cancer Prevalence and Cost-Effective Oncology Treatments

Bevacizumab Biosimilars Market Revenue Set to Double by 2032 Amid Rising Global Cancer Burden

The Bevacizumab Biosimilars Market was valued at USD 1.86 billion in 2024 and is expected to expand to USD 3.70 billion by 2032, reflecting a CAGR of 9.01% during 2025–2032. Rising global cancer prevalence, including colorectal, lung, glioblastoma, and renal cell carcinomas, is fueling the demand for biosimilars that offer cost-effective, high-efficacy alternatives to originator biologics. According to the World Health Organization, cancer cases are projected to rise by 77% by 2050, underscoring the urgent need for accessible oncology treatments.

Biosimilars are generally priced 15%–30% lower than their originator counterparts, making them attractive to healthcare systems aiming to reduce financial toxicity associated with cancer treatment. U.S. sales of biosimilars are anticipated to double between 2021 and 2023, reflecting growing acceptance among clinicians and payers.

Track the Latest Market Developments: Request a Sample Report: https://www.snsinsider.com/sample-request/7308

Market Dynamics Driven by Increasing Adoption of Cost-Effective Biologics in Oncology

Countries with biosimilar substitution policies have experienced significant market share gains, with more than 80% of oncology biosimilars in the European Union achieving parity with originator products. In the U.S., favorable formulary placements, support from the Agency for Healthcare Research and Quality (AHRQ), and Medicare reimbursement parity have accelerated biosimilar adoption.

Clinical evidence continues to bolster confidence. At ASCO 2025, data demonstrated that a bevacizumab biosimilar delayed cancer progression in metastatic colorectal cancer comparably to the originator, supporting its integration into standard treatment guidelines.

Research and development investments remain strong, with Biocon, Amgen, and Pfizer dedicating resources to analytical characterization, immunogenicity testing, and real-world data collection. Global biosimilar R&D spending exceeded USD 2.4 billion in 2024, with over 20 Phase III oncology trials underway. Regulatory agencies including the FDA and EMA have expanded biosimilar review teams by 25%, reducing approval timelines by 40%.

U.S. Bevacizumab Biosimilars Market Expands with Medicare Support and Payer Incentives

The U.S. Bevacizumab Biosimilars Market was valued at USD 0.50 billion in 2024 and is expected to reach USD 0.91 billion by 2032, registering a CAGR of 7.81%. Drivers include the high cancer burden, payer preference for biosimilars, and strong hospital adoption. Programs such as the FDA’s Biosimilar Action Plan and accelerated review processes have shortened time to market, while real-world evidence (RWE) and head-to-head clinical trials by Innovent and Coherus have enhanced prescriber confidence.

Supply chain improvements, including regional manufacturing centers in India, South Korea, and Eastern Europe, ensure better accessibility and shorter lead times. Licensing collaborations, such as Biocon-Mylan and Amgen-BeiGene, further facilitate global expansion. Updates to the WHO Essential Medicines List in 2025 incorporated bevacizumab biosimilars as central to oncology care, supporting their status as high-value interventions.

Key Drivers and Restraints Shaping the Global Bevacizumab Biosimilars Market

The primary drivers include increasing cancer prevalence, demand for cost-effective biologics, and supportive policies encouraging biosimilar adoption. Over 10 million new cases of cancers eligible for anti-VEGF therapy are expected each year, fueling biosimilar uptake. Pharmaceutical companies, including Samsung Bioepis, have invested heavily to expand their pipelines, while accelerated regulatory pathways in the U.S. and EU have shortened approval times. Hospital formularies and payer programs now support a 65% penetration rate for Medicare oncology treatment in the U.S., integrating biosimilars into standard care.

Challenges include physician hesitancy due to immunogenicity concerns, patent barriers, and limited interchangeability approvals. Only four biosimilars are currently designated interchangeable by the FDA, none of which include bevacizumab. Variability in reimbursement policies, underdeveloped pharmacovigilance systems, and educational gaps among healthcare providers also restrain market expansion. Smaller companies face significant entry costs of USD 100–250 million, limiting competitive pressure in the market.

Product Segment Analysis Highlights Mvasi’s Market Leadership and Zirabev’s Rapid Growth

Mvasi, developed by Amgen, accounted for 38% of the market in 2024, benefiting from early U.S. FDA approval, strong clinical equivalency data, and aggressive commercial strategies. Its inclusion in hospital formularies and insurance coverage across major regions has reinforced its leading position. Partnerships with BeiGene and other international licensing arrangements facilitated its rapid adoption in Asian markets.

Zirabev, developed by Pfizer, emerged as the fastest-growing product, driven by aggressive pricing, international launches, and penetration into underserved oncology markets in Latin America and Southeast Asia. Growing oncologist preference and patient demand contributed to high double-digit growth in 2024.

Application Segment Analysis Shows Colorectal Cancer Dominance, Lung Cancer Gaining Traction

Colorectal cancer accounted for nearly 32% of the global market in 2024, reflecting the disease’s substantial burden of 1.9 million new annual cases. Bevacizumab biosimilars delivered superior results in metastatic colorectal cancer when combined with chemotherapy, earning recommendations in NCCN and ESMO oncology guidelines.

Non-small cell lung cancer (NSCLC) emerged as the fastest-growing application, supported by regulatory approvals and real-world evidence showing equivalence to originator drugs. Rising lung cancer incidence and cost constraints with branded Avastin have facilitated early biosimilar adoption in NSCLC therapy.

Distribution Channel Trends Indicate Hospitals Lead, Online Pharmacies Poised for Rapid Expansion

Hospital pharmacies accounted for 54% of global sales in 2024, driven by centralized oncology treatment, payer reimbursement models, and institutional purchasing contracts favoring biosimilars. Intravenous administration and monitoring requirements reinforce hospital-based adoption.

Online pharmacies emerged as the fastest-growing channel, spurred by digital healthcare infrastructure, telehealth services, and patient preference for home delivery. Markets in Asia and North America saw significant double-digit growth in 2024, a trend expected to continue as outpatient and homecare administration expands.

Interest in Market Trends: Get Detailed Analysis and Insights with Our Comprehensive Report: https://www.snsinsider.com/reports/bevacizumab-biosimilars-market-7308

Regional Insights Highlight North America’s Dominance and Asia Pacific’s Rapid Market Expansion

North America led the market in 2024 due to early approvals, favorable reimbursement, and high awareness of biosimilars in oncology practices. The U.S., with over 1.9 million new cancer cases in 2023, drives adoption through Medicare and Medicaid coverage. Canada’s pan-Canadian Pharmaceutical Alliance negotiates favorable pricing, while Mexico is emerging with aligned regulations and public procurement initiatives.

Europe follows, benefiting from EMA approvals, national tendering systems, and automatic substitution policies. Germany, France, Spain, and Poland report high biosimilar penetration supported by clinical guidelines and EU funding. Asia Pacific recorded the fastest growth in 2024, with China leading through NRDL listings and volume procurement initiatives. India, Japan, South Korea, and Singapore also contribute to the region’s rapid expansion through affordable biosimilars, expedited approvals, and healthcare reforms.

Leading Market Participants Contributing to Global Expansion

Amgen, AryoGen, Pharmed, Biothera, Boehringer Ingelheim, Centus Biotherapeutics, Henlius Biotech, Innovent Biologics, Mylan, mAbxience, Outlook Therapeutics, Pfizer, Prestige Biopharma, Roche, Samsung Bio, TOT Biopharm

Future Outlook Indicates Sustained Market Growth Fueled by Innovation and Accessibility

The Bevacizumab Biosimilars Market is expected to maintain strong growth through 2032, driven by rising cancer incidence, cost-containment strategies, and continued investment in R&D. Expansion into emerging markets, coupled with regulatory support and real-world evidence generation, is likely to enhance adoption further. Digital healthcare channels and outpatient delivery models will strengthen accessibility, while licensing agreements and partnerships will support global penetration. Ongoing clinical trials, coupled with supportive policies and cost-effectiveness analyses, position bevacizumab biosimilars as a critical element in affordable oncology care.

Conclusion: Bevacizumab Biosimilars Set to Transform Affordable Cancer Care Globally

Rising cancer prevalence, demand for cost-effective biologics, and global regulatory support are fueling unprecedented growth in the bevacizumab biosimilars market. With expanding clinical evidence, robust R&D investments, and increasing hospital and digital adoption, biosimilars are poised to provide high-efficacy, affordable treatment options to patients worldwide, reshaping the future of oncology care.

Other Trending Reports

Veterinary Stereotactic Radiosurgery System Market

Intravenous catheters Market

Hematology Analyzers Market

Skin Cancer Treatment Market